نمایش مختصر رکورد

dc.contributor.authorBeheshti, Farimahen_US
dc.contributor.authorHosseini, Mahmouden_US
dc.contributor.authorHashemzehi, Miladen_US
dc.contributor.authorSoukhtanloo, Mohammaden_US
dc.contributor.authorKhazaei, Majiden_US
dc.contributor.authorShafei, Mohammad Naseren_US
dc.date.accessioned1399-07-09T08:24:09Zfa_IR
dc.date.accessioned2020-09-30T08:24:09Z
dc.date.available1399-07-09T08:24:09Zfa_IR
dc.date.available2020-09-30T08:24:09Z
dc.date.issued2019-08-01en_US
dc.date.issued1398-05-10fa_IR
dc.date.submitted2018-11-11en_US
dc.date.submitted1397-08-20fa_IR
dc.identifier.citationBeheshti, Farimah, Hosseini, Mahmoud, Hashemzehi, Milad, Soukhtanloo, Mohammad, Khazaei, Majid, Shafei, Mohammad Naser. (2019). The effects of PPAR-γ agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats. Iranian Journal of Basic Medical Sciences, 22(8), 940-948. doi: 10.22038/ijbms.2019.36165.8616en_US
dc.identifier.issn2008-3866
dc.identifier.issn2008-3874
dc.identifier.urihttps://dx.doi.org/10.22038/ijbms.2019.36165.8616
dc.identifier.urihttp://ijbms.mums.ac.ir/article_13239.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/340734
dc.description.abstract<em><strong>Objective(s):</strong></em> The aim of current study was to evaluate improving effects of pioglitazone as an agonist of peroxisome proliferator-activated receptor gamma (PPARγ), on brain-derived neurotrophic factor (BDNF) and cytokines as well as tissue oxidative damage criteria in the hippocampus in a rat model of lipopolysaccharide (LPS) induced memory impairment.<br /><em><strong>Materials and Methods:</strong></em> The rats were classified and treated as follows (10 rats per group): (1) vehicle, (2) vehicle before LPS (1 mg/kg, 120 min before memory tests), (3-5) pioglitazone 10, 20 or 30 mg/kg 30 min before LPS. Finally, the hippocampal tissues were collected for biomedical analyses.<br /><em><strong>Results:</strong></em> In the Morris water maze test, the LPS group, had a longer latency to find the platform while they spent a shorter time in the target quadrant in the probe trial. In the passive avoidance test, the animals of the LPS group had shorter delay times to enter the dark compartment than those of the control group. Treatment with 20 and 30 mg of pioglitazone corrected these parameters. In the hippocampus of LPS group interleukin-6, tumor necrosis factor-α, nitric oxide metabolites, and malondialdehyde were higher while  thiol, BDNF, and IL-10 concentrations and the activities of catalase (CAT) and superoxide dismutase (SOD) were lower than the control group. Treatment by both doses of 20 and 30 mg of pioglitazone corrected the biochemical parameters in the hippocampus.<br /> <em><strong>Conclusion:</strong></em> The current findings revealed that pioglitazone protected the rats from learning and memory impairment induced by LPS. The effects were associated with improvement of cytokines, oxidative stress criteria, and BDNF.en_US
dc.format.extent1496
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherMashhad University of Medical Sciencesen_US
dc.relation.ispartofIranian Journal of Basic Medical Sciencesen_US
dc.relation.isversionofhttps://dx.doi.org/10.22038/ijbms.2019.36165.8616
dc.subjectBrain-derived neurotrophic- factoren_US
dc.subjectCytokines learningen_US
dc.subjectLipopolysaccharideen_US
dc.subjectMemoryen_US
dc.subjectPioglitazoneen_US
dc.subjectPhysiologyen_US
dc.titleThe effects of PPAR-γ agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated ratsen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentDivision of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentDivision of Neurocognitive Sciences, Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentIranshahr University of Medical Sciences, Iranshahr, Iranen_US
dc.contributor.departmentDepartment of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentNeurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.contributor.departmentDepartment of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iranen_US
dc.citation.volume22
dc.citation.issue8
dc.citation.spage940
dc.citation.epage948
nlai.contributor.orcid0000-0003-1524-2339
nlai.contributor.orcid0000-0001-6425-5123
nlai.contributor.orcid0000-0001-5148-9895


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد